Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Alfosbuvir and Daclatasvir in Healthy Men
NCT03748745Phase 1Completed
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Nov 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aoxibuvir in hepatitis C (HCV) (2 cohorts), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoint: Incidence of adverse events. Started Nov 2018; status: completed.
02
Drugs
aoxibuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03748745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748745.